Results 91 to 100 of about 2,068,953 (291)

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

Molecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Clinical challenges and patient experiences in early-onset colorectal cancer: insights from seven European countries

BMC Gastroenterology
Background The incidence of early-onset colorectal cancer (eoCRC), defined as CRC diagnosed in individuals under 50, is rising globally. Younger patients often face diagnostic delays and receive care pathways designed for older populations.
Marianna Vitaloni, Katell Maguet, Andi Carlan, Patricia Stack, Vincent de Jong, Ross Williams, Zorana Maravic   +6 more
doaj   +1 more source

The Reception of William Beaumont's Discovery in Europe [PDF]

, 1942

openalex   +1 more source

Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer

Molecular Oncology, EarlyView.
Analysis of treatment‐naïve high‐grade serous ovarian carcinoma (HGSOC) and control tissues for ERVs, LINE‐1 (L1), inflammation, and immune checkpoints identified five clusters with diverse patient recurrence‐free survivals. An inflammation score was calculated and correlated with retroelement expression, where one novel cluster (Triple‐I) with high ...
Laura Glossner, Markus Eckstein, Christoph Mark, Matthias W. Beckmann, Arndt Hartmann, Pamela L. Strissel, Reiner Strick   +6 more
wiley   +1 more source

The Healthcare Professionals’ and Patient Advocates’ Perspectives on the Care for Children with Cancer in Europe—A Report from the ESCALIER Project

Current Oncology
Cancer in children and adolescents is rare. Therefore, experienced multidisciplinary teams of health care professionals and input from patient advocates are needed.
Maria Otth, Marko Ocokoljic, Theodora Armenkova, Irina Ban, Samira Essiaf, Maximilian Hopfgartner, Lejla Kameric, Pamela R. Kearns, Georgia Kokkinou, Carmelo Rizzari, Carina Schneider, Katrin Scheinemann   +11 more
doaj   +1 more source

Isolation of Palustric Acid from the Oleoresins of North-European Pine and Spruce by Partition Chromatography. [PDF]

, 1959
Henrik H. Bruun, Stein Gåsland, Gunnar Lundqvist, Björn Högberg, P. Kneip, H. Palmstierna   +5 more
openalex   +1 more source

Politeness in Europe

Studies in Applied Linguistics & TESOL, 2005
Is this true of all Westerners? And what exactly do we mean by Westerner? If a similar exchange were to take place, say, in an elevator in Helsinki, could we draw the same conclusions? Indeed, would such an exchange take place in Helsinki at all? In Nicosia? In Tallinn? Leo Hickey and Miranda Stewart’s delightful new volume, Politeness in Europe, takes
openaire   +4 more sources

EGFR‐STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1‐positive prostate cancer

Molecular Oncology, EarlyView.
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva, Bernardo Orr, Ana Azeredo, Andreia Brandão, Manuel R. Teixeira, Paula Paulo   +5 more
wiley   +1 more source

Axis Rule in Occupied Europe: Laws of Occupation, Analysis of Government, Proposals for Redress [PDF]

, 1945
Linden A. Mander, Raphael Lemkin
openalex   +1 more source

Integrative miRNOMe profiling reveals the miR‐195‐5p–CHEK1 axis and its impact on luminal breast cancer outcomes

Molecular Oncology, EarlyView.
In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková, Marie Ehrlichová, Alžběta Spálenková, Ivona Krus, Simona Šůsová, Viktor Hlaváč, Vlasta Němcová, Renata Koževnikovová, Markéta Trnková, David Vrána, Jiří Gatěk, Kateřina Kopečková, Marcela Mrhalová, Soňa Měšťáková, Pavel Souček   +14 more
wiley   +1 more source